Ixekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study
Despite high comorbidity burden and majority of the patients being biologic-experienced, patients initiating ixekizumab for axSpA showed favorable persistence profiles during the 12-month follow-up period.
Authors
- Jeffrey Lisse (ORCID: https://orcid.org/0000-0003-0359-4492)
- Abhijeet Danve (ORCID: https://orcid.org/0000-0002-3032-0828)
- Aisha Vadhariya (ORCID: https://orcid.org/0000-0002-1811-5370)
- Catherine Bakewell (ORCID: https://orcid.org/0000-0003-2367-0640)
- Neha Bansal (ORCID: https://orcid.org/0009-0008-9446-3132)
- Natalia Bello (ORCID: https://orcid.org/0000-0001-5042-9460)
- Arjun Cholayil (ORCID: https://orcid.org/0009-0002-7353-8461)
Institutions
- Intermountain Healthcare (US)
- Eli Lilly (United States) (US)
- Yale University (US)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1007/s40744-024-00710-0
- Citations
- 3
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- Eli Lilly and Company